These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 19435870

  • 1. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.
    Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S.
    Mol Cancer Ther; 2009 May; 8(5):1207-17. PubMed ID: 19435870
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
    Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, Colon J, Smith J, Safe S, Maliakal P, Basha R.
    Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
    [Abstract] [Full Text] [Related]

  • 5. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.
    Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M.
    Invest New Drugs; 2011 Feb; 29(1):41-51. PubMed ID: 19851711
    [Abstract] [Full Text] [Related]

  • 6. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met.
    Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S.
    Carcinogenesis; 2009 Jul; 30(7):1193-201. PubMed ID: 19406933
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
    Chadalapaka G, Jutooru I, Sreevalsan S, Pathi S, Kim K, Chen C, Crose L, Linardic C, Safe S.
    Int J Cancer; 2013 Feb 15; 132(4):795-806. PubMed ID: 22815231
    [Abstract] [Full Text] [Related]

  • 8. Tolfenamic Acid Inhibits the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma: Involvement of p38-Mediated Down-Regulation of Slug.
    Jittreetat T, Shin YS, Hwang HS, Lee BS, Kim YS, Sannikorn P, Kim CH.
    Yonsei Med J; 2016 May 15; 57(3):588-98. PubMed ID: 26996556
    [Abstract] [Full Text] [Related]

  • 9. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
    Parris AB, Zhao Q, Howard EW, Zhao M, Ma Z, Yang X.
    J Exp Clin Cancer Res; 2017 Feb 13; 36(1):28. PubMed ID: 28193239
    [Abstract] [Full Text] [Related]

  • 10. Effect of tolfenamic acid on canine cancer cell proliferation, specificity protein (sp) transcription factors, and sp-regulated proteins in canine osteosarcoma, mammary carcinoma, and melanoma cells.
    Wilson H, Chadalapaka G, Jutooru I, Sheppard S, Pfent C, Safe S.
    J Vet Intern Med; 2012 Feb 13; 26(4):977-86. PubMed ID: 22536857
    [Abstract] [Full Text] [Related]

  • 11. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation.
    Chang JW, Kang SU, Choi JW, Shin YS, Baek SJ, Lee SH, Kim CH.
    Free Radic Biol Med; 2014 Feb 13; 67():115-30. PubMed ID: 24216474
    [Abstract] [Full Text] [Related]

  • 12. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
    Abdelrahim M, Baker CH, Abbruzzese JL, Safe S.
    J Natl Cancer Inst; 2006 Jun 21; 98(12):855-68. PubMed ID: 16788159
    [Abstract] [Full Text] [Related]

  • 13. Tolfenamic acid induces apoptosis and growth inhibition in head and neck cancer: involvement of NAG-1 expression.
    Kang SU, Shin YS, Hwang HS, Baek SJ, Lee SH, Kim CH.
    PLoS One; 2012 Jun 21; 7(4):e34988. PubMed ID: 22536345
    [Abstract] [Full Text] [Related]

  • 14. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression.
    Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M.
    Mol Cancer Ther; 2009 Mar 21; 8(3):533-42. PubMed ID: 19258429
    [Abstract] [Full Text] [Related]

  • 15. The involvement of lipid raft pathway in suppression of TGFβ-mediated metastasis by tolfenamic acid in hepatocellular carcinoma cells.
    Sun J, Tao R, Mao T, Feng Z, Guo Q, Zhang X.
    Toxicol Appl Pharmacol; 2019 Oct 01; 380():114696. PubMed ID: 31381904
    [Abstract] [Full Text] [Related]

  • 16. Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.
    Hurtado M, Sankpal UT, Kaba A, Mahammad S, Chhabra J, Brown DT, Gurung RK, Holder AA, Vishwanatha JK, Basha R.
    Cell Physiol Biochem; 2018 Oct 01; 51(4):1894-1907. PubMed ID: 30504717
    [Abstract] [Full Text] [Related]

  • 17. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells.
    Sankpal UT, Goodison S, Jones-Pauley M, Hurtado M, Zhang F, Basha R.
    Oncotarget; 2017 Feb 28; 8(9):14593-14603. PubMed ID: 28099934
    [Abstract] [Full Text] [Related]

  • 18. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
    Lee H, Saini N, Howard EW, Parris AB, Ma Z, Zhao Q, Zhao M, Liu B, Edgerton SM, Thor AD, Yang X.
    Sci Rep; 2018 May 01; 8(1):6829. PubMed ID: 29717218
    [Abstract] [Full Text] [Related]

  • 19. Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer.
    Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S.
    Mol Cancer Ther; 2012 Jul 01; 11(7):1421-31. PubMed ID: 22553354
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
    Wang LH, Chan JL, Li W.
    Int J Cancer; 2007 Jul 01; 121(1):157-64. PubMed ID: 17304506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.